US Patent 5,344,840: Dexmedetomidine Perioperative Treatment Claims, Scope, Expiration, and Patent Landscape

US Patent 5,344,840 covered the perioperative use of dexmedetomidine, the dextro enantiomer of medetomidine, to reduce autonomic responses to surgical stress. The patent did not broadly claim dexmedetomidine as a chemical compound or all uses of dexmedetomidine. Its claims were method-of-treatment claims focused on preoperative administration, anxiolytic and analgesic premedication, sedation, and reduction of anesthetic requirements.

The patent issued on September 6, 1994. Because it was subject to the pre-June 8, 1995 patent-term regime, its ordinary term was 17 years from issuance, producing an expected expiration date of September 6, 2011, absent a terminal disclaimer or other term adjustment. The patent is therefore expired and cannot currently block generic or branded dexmedetomidine products.

What drug and medical use does US Patent 5,344,840 cover?

The claimed active ingredient is dexmedetomidine, chemically identified as dextro 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, or a non-toxic pharmaceutically acceptable salt.

Dexmedetomidine is the pharmacologically active alpha-2 adrenergic agonist enantiomer of medetomidine. In the United States, it has been marketed primarily as dexmedetomidine hydrochloride injection under the brand name Precedex.

The patent addresses administration around surgery. Its central objective is reducing autonomic nervous-system responses to stressful stimuli during an operation. Relevant responses can include sympathetic activation, tachycardia, hypertension, agitation, and other physiologic reactions associated with surgical stress or anesthesia.

The patent does not claim:

Dexmedetomidine as a chemical entity in the abstract.
All pharmaceutical compositions containing dexmedetomidine.
Every use of dexmedetomidine in intensive-care or procedural sedation.
A particular dosage, concentration, vial, syringe, infusion pump, or excipient system.
A specific surgical procedure.
A particular patient age group or disease state.
A required route of administration.

What are the claims of US Patent 5,344,840?

Claim	Legal subject matter	Scope
1	Perioperative treatment method	Administration of dexmedetomidine or a pharmaceutically acceptable salt to a mammal to reduce autonomic responses to surgical stress, substantially without the levo form
2	Narrowed method	Claim 1 where dexmedetomidine is used as anxiolytic and analgesic premedication, with or without local or general anesthesia
3	Narrowed method	Claim 1 where dexmedetomidine is used preoperatively as sedative analgesia to potentiate anesthesia and reduce the anesthetic amount required

Claim 1 is the broadest independent claim. Claims 2 and 3 depend on claim 1 and add specific therapeutic contexts.

The key structural limitation is the requirement that the administered material be substantially free of the levo form. This limitation distinguishes dexmedetomidine from racemic medetomidine and focuses the claim on the dextro enantiomer.

How should claim 1 be construed?

Claim 1 contains several separate limitations that would have mattered in an infringement analysis.

Perioperative treatment

The treatment must relate to an operation. The claim is directed to administration before or during surgery, rather than an unrelated outpatient, chronic, diagnostic, or nonsurgical use.

The term "perioperative" is broader than "preoperative" in ordinary medical usage. It can encompass treatment before, during, and around an operation. Claims 2 and 3 narrow the timing by expressly requiring preoperative administration.

Reduction of autonomic responses

The treatment must be intended to reduce responses of the autonomic nervous system to stressful stimuli during an operation. The claim is therefore functional. It does not require a particular numerical reduction in blood pressure, heart rate, catecholamine levels, or anesthetic dose.

A product used in surgery would not automatically fall within the claim merely because it contains dexmedetomidine. The relevant use, treatment intent, and relationship to autonomic stress responses would matter.

Effective amount

The administered quantity must be effective for the claimed purpose. The patent does not impose a fixed loading dose, infusion rate, concentration, or duration.

This omission gives the claim breadth across dosing regimens, but it also makes the therapeutic-purpose limitation important. A dexmedetomidine product used for an unrelated purpose would not necessarily practice the claim.

Substantial absence of the levo form

The claim requires dexmedetomidine "substantially in the absence" of levomedetomidine. This is a stereochemical purity limitation. It does not necessarily require absolute enantiomeric purity, but it excludes a material containing the levo form in a clinically meaningful or non-incidental amount.

The claim could therefore reach dexmedetomidine formulations with minor residual levels of the opposite enantiomer, depending on the applicable construction of "substantially in the absence."

What do claims 2 and 3 add?

Claim 2: anxiolytic and analgesic premedication

Claim 2 covers use before an operation as anxiolytic and analgesic premedication. The method may be combined with local or general anesthesia, or administered without an anesthetic sufficient to produce the desired level of anesthesia.

This claim targets the preoperative medication role of dexmedetomidine. It requires more than sedation alone because the claim characterizes the use as anxiolytic and analgesic premedication.

Claim 3: anesthetic-sparing sedation and analgesia

Claim 3 covers preoperative use as sedative analgesia to potentiate anesthesia and reduce the amount of anesthetic needed to reach the desired level of anesthesia.

The anesthetic-sparing limitation is the principal distinction from claim 2. Evidence relevant to this claim would include:

The anesthetic dose administered with and without dexmedetomidine.
The target depth or level of anesthesia.
Whether dexmedetomidine potentiated the anesthetic effect.
The physician’s treatment objective.
Clinical protocols or labeling describing reduction of anesthetic requirements.

A formulation manufacturer generally would not infringe claim 3 merely by selling dexmedetomidine. Liability would more likely depend on the use instructions, prescribing information, promotional materials, or induced-use theory.

When did US Patent 5,344,840 expire?

Event	Date or status
Patent issued	September 6, 1994
Applicable term regime	17 years from grant for a pre-June 8, 1995 application
Expected ordinary expiration	September 6, 2011
Current status	Expired
Current blocking effect	None for United States market entry

The patent’s expiration removed the principal U.S. method-of-use barrier associated with perioperative dexmedetomidine treatment. Any patent-term-extension analysis would depend on the specific regulatory history and statutory eligibility. Patent-term extension generally applies to qualifying regulatory delay and not to every patent covering an approved drug. The 2011 expiration date is the relevant historical endpoint for this patent’s enforceability.

What is the Orange Book status of US Patent 5,344,840?

The FDA Orange Book lists patents identified by an NDA holder as covering an approved drug or method of use. Precedex, dexmedetomidine hydrochloride injection, was approved under an NDA held by Hospira, following development and commercialization associated with Abbott and its affiliates.

US Patent 5,344,840 was historically associated with the Precedex patent estate and the perioperative use of dexmedetomidine. Its expiration means that it is not a current Orange Book barrier to an abbreviated new drug application or generic launch.

Orange Book analysis should distinguish among:

Listed patents that have expired.
Unexpired formulation or method-of-use patents.
Patent delistings.
Pediatric exclusivity.
Regulatory exclusivity that is separate from patent rights.

The expiration of 5,344,840 did not itself determine whether every later patent in the Precedex estate had expired. It removed this specific patent’s protection.

How strong was the patent estate for dexmedetomidine?

The patent estate was strongest historically in three areas:

Estate segment	Protection theory	Relevance
Chemical compound patents	Dexmedetomidine and related imidazole derivatives	Protected the active molecule and stereochemical class
Method-of-use patents	Perioperative, sedative, analgesic, and anesthetic-sparing uses	Covered clinical administration objectives
Product and formulation patents	Injectable preparations, concentrations, containers, or delivery formats	Potentially relevant after compound-patent expiry

US Patent 5,344,840 was a use patent rather than a core compound patent. Its commercial importance arose from the way dexmedetomidine was deployed clinically, not from ownership of the molecule itself.

The claim set was relatively narrow in one respect: it required perioperative treatment and substantial absence of the levo enantiomer. It was broader in another respect because it did not specify a dose, route, anesthetic, surgery type, or formulation.

Its practical strength depended on the approved indication and prescribing instructions. A product label that directed preoperative anxiolytic, analgesic, or anesthetic-sparing use could have created greater exposure than a label limited to intensive-care sedation.

Which companies challenged or entered the dexmedetomidine market?

Dexmedetomidine generic entry occurred after expiration of the principal blocking rights and through FDA ANDA approvals. Known commercial participants have included Hospira and later Pfizer, as well as other generic injectable manufacturers.

The relevant competitive groups have been:

The Precedex reference-product business.
Generic dexmedetomidine hydrochloride injection suppliers.
Hospital injectable manufacturers.
Companies marketing premixed bags, ready-to-use presentations, or alternative concentrations.

The main competitive issue has been supply, hospital contracting, presentation, and injectable manufacturing capacity rather than an active dispute over the expired claims of US 5,344,840.

There is no biosimilar pathway for dexmedetomidine. Dexmedetomidine is a small-molecule drug, so competitive entry occurs through the ANDA pathway, not through a 351(k) biosimilar application.

What FDA regulatory status applies to dexmedetomidine?

The FDA approved Precedex as dexmedetomidine hydrochloride injection for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive-care setting. The FDA later approved additional use for procedural sedation in non-intubated patients. The Precedex label identifies dexmedetomidine hydrochloride as an alpha-2 adrenergic agonist.[1]

The FDA-approved indications are narrower than the full theoretical scope of claim 1. Claim 1 concerns perioperative reduction of autonomic responses and includes an operation-related use. Current labeling and clinical practice must therefore be analyzed separately from the historical patent language.

Off-label perioperative use may still be medically practiced, but an expired patent cannot be asserted against that use in the United States.

What generic entry risks remain after expiration?

US Patent 5,344,840 creates no present generic entry risk because it is expired. The remaining risks would arise from other sources:

Formulation patents

A later patent could cover a specific concentration, excipient, stability profile, premixed bag, syringe, or container closure. Such a patent would not be defeated merely by expiration of the perioperative method patent.

Manufacturing patents

Dexmedetomidine production may involve stereoselective synthesis, resolution, purification, salt formation, crystallization, or impurity-control processes. Process patents can create supply-chain risk even after product and method patents expire, although generic manufacturers can often design around them or use alternative processes.

Labeling and induced infringement

A generic company can reduce method-of-use exposure through a carve-out, also known as a section viii statement, where an unprotected use is omitted from labeling. The risk depends on whether the remaining label, promotional activity, or clinical instructions encourage a patented use.

For this patent, that issue is historical because the claims are expired.

Regulatory exclusivity

Regulatory exclusivity is separate from patent protection. Any applicable exclusivity period would have been tied to the NDA and FDA approval dates, not to the September 2011 patent expiration. No current exclusivity associated with this 1994 patent blocks ANDA approval.

How does this patent compare with a compound patent?

Issue	US Patent 5,344,840	Compound patent
Protection type	Method of treatment	Chemical compound or composition
Coverage	Perioperative dexmedetomidine use	Molecule, salt, stereoisomer, or chemical class
Direct product blocking power	Limited	Usually stronger
Dependence on labeling and use	High	Lower
Expiration effect	Removes protection for claimed use	Removes core molecule barrier
Design-around options	Alternative indication or label	More difficult before compound expiry

A compound patent ordinarily has greater commercial leverage because it can block manufacture, sale, and use of the active ingredient. US 5,344,840 was narrower but clinically targeted. Its value depended on whether dexmedetomidine was promoted or prescribed for the claimed perioperative purposes.

What patent litigation and settlement activity affected this patent?

No current enforceable litigation threat arises from US Patent 5,344,840 because the patent expired in 2011. Publicly available FDA and patent records identify the patent as part of the historical Precedex intellectual-property framework, but the claim set no longer provides a basis for an injunction against a current U.S. generic entrant.

A historical Paragraph IV challenge would have been relevant only before expiration. After expiration, the commercial value of such a challenge largely disappears because an ANDA applicant does not need to invalidate an expired patent to launch, subject to any separate unexpired patents or regulatory exclusivities.

No settlement agreement is required to resolve an expired patent. Any settlement involving later Precedex patents would need separate analysis and would not revive the enforceability of 5,344,840.

Key takeaways

US Patent 5,344,840 covered perioperative treatment with dexmedetomidine, not the molecule in all contexts.
Claim 1 required reduction of autonomic responses to operative stress and substantial absence of the levo enantiomer.
Claims 2 and 3 addressed preoperative anxiolytic and analgesic premedication and anesthetic-sparing use.
The patent issued September 6, 1994 and ordinarily expired September 6, 2011.
It is not a current barrier to generic dexmedetomidine entry.
The patent had no specified dose, route, formulation, surgery type, or anesthetic.
Dexmedetomidine is a small molecule and faces ANDA competition, not biosimilar competition.
Current diligence should focus on later formulation, manufacturing, packaging, and unexpired method-of-use patents rather than 5,344,840.

FAQs about US Patent 5,344,840 and dexmedetomidine

Does US Patent 5,344,840 cover Precedex itself?

No. It covers specified perioperative uses of dexmedetomidine. It does not, by itself, claim every Precedex product or every use of dexmedetomidine.

Can a generic manufacturer launch dexmedetomidine despite this patent?

Yes. The patent expired in 2011 and no longer blocks U.S. manufacture, approval, sale, or use.

Did the patent cover dexmedetomidine hydrochloride?

The claims cover dexmedetomidine and non-toxic pharmaceutically acceptable salts. Dexmedetomidine hydrochloride is within the salt language when used for the claimed perioperative purposes.

Is dexmedetomidine subject to biosimilar competition?

No. Dexmedetomidine is a small-molecule active ingredient. Generic versions are approved through the ANDA pathway.

What is the main remaining IP risk for a dexmedetomidine injectable?

The principal potential risks are later patents covering formulation, concentration, container systems, manufacturing processes, or specific labeled uses. Those rights must be reviewed independently from US Patent 5,344,840.

References

U.S. Food and Drug Administration. (n.d.). Precedex (dexmedetomidine hydrochloride) injection prescribing information. FDA.
U.S. Patent and Trademark Office. (1994). U.S. Patent No. 5,344,840: Use of dexmedetomidine as a preanesthetic medication. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Code, Title 35, §§ 154, 156, and 271.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8804683	Feb 29, 1988

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	101514	⤷ Start Trial
Australia	3027289	⤷ Start Trial
Australia	611262	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,344,840

Summary for Patent: 5,344,840